Literature DB >> 19995716

Immunohistochemical evaluation of Ki-67, PCNA and MCM2 proteins proliferation index (PI) in advanced gastric cancer.

Jolanta Czyzewska1, Katarzyna Guzińska-Ustymowicz, Anna Pryczynicz, Andrzej Kemona, Roman Bandurski.   

Abstract

The current study objective was to assess the proliferation indices (PI) of Ki-67, PCNA and MCM2 proteins in advanced gastric cancer and in metastatic lymph node in correlation with certain clinicopathological features and with postoperative survival of patients. The study was conducted in a group of 100 patients with advanced gastric cancers. Involvement of local lymph nodes was present in 36 cases. Immunohistochemical investigations were carried out using monoclonal antibodies against Ki-67 (DAKO), PCNA (DAKO) and polyclonal antibody to MCM2 (Santa Cruz Biotechnology). Visualization of the antigen/antibody complex was performed using LSAB technique (biotin-streptavidin-peroxidase) followed by application of chromogene DAB (DAKO). Statistical analysis revealed no correlations of Ki-67, PCNA and MCM2 PI in tumour tissue or metastatic lymph node with patients' age and gender, tumour location, histological grade, macroscopic type according to Bormann's classification and histological grading by Lauren's and Goseki's classifications. Moreover, no correlation was observed of Ki-67 and MCM2 PI in tumour tissue with histological grading. No correlation was also noted between the proliferation indices of all the three proteins in the affected lymph node and grade of histological differentiation. Such clinicopathological parameters as patients' age and gender, histological grading by Lauren's and Goseki's classifications and lymph node involvement did not correlate with survival time of patients. Furthermore, no statistically significant correlation was shown of postoperative survival time with Ki-67 and MCM2 PI in tumour tissue and metastatic lymph nodes and with PCNA PI in the affected lymph nodes. However, a statistically significant correlation was found of Ki-67, PCNA and MCM2 PI in tumour tissue and metastatic lymph nodes with depth of wall invasion and local lymph node involvement. A statistically significant correlation was also noted between PCNA PI in the main mass of tumour and histological grading. The postoperative survival time of patients exhibited a statistically significant correlation with tumour location and macroscopic type according to Bormann's classification. Correlations on statistical borderline were noted between survival time and depth of gastric wall invasion and PCNA PI in the main mass of tumour.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19995716     DOI: 10.2478/v10042-009-0042-y

Source DB:  PubMed          Journal:  Folia Histochem Cytobiol        ISSN: 0239-8508            Impact factor:   1.698


  16 in total

1.  Protein signatures for classification and prognosis of gastric cancer a signaling pathway-based approach.

Authors:  Daguang Wang; Fei Ye; Yabin Sun; Wei Li; Hongyi Liu; Jing Jiang; Yang Zhang; Chengkui Liu; Weihua Tong; Ling Gao; Yezhou Sun; Weijia Zhang; Terry Seetoe; Peng Lee; Jian Suo; David Y Zhang
Journal:  Am J Pathol       Date:  2011-08-18       Impact factor: 4.307

2.  Prognostic evaluation of Nanog, Oct4, Sox2, PCNA, Ki67 and E-cadherin expression in gastric cancer.

Authors:  Ning Li; Wenying Deng; Jie Ma; Bing Wei; Kang Guo; Wei Shen; Yanping Zhang; Suxia Luo
Journal:  Med Oncol       Date:  2014-12-10       Impact factor: 3.064

3.  All-trans retinoic acid targets gastric cancer stem cells and inhibits patient-derived gastric carcinoma tumor growth.

Authors:  P H Nguyen; J Giraud; C Staedel; L Chambonnier; P Dubus; E Chevret; H Bœuf; X Gauthereau; B Rousseau; M Fevre; I Soubeyran; G Belleannée; S Evrard; D Collet; F Mégraud; C Varon
Journal:  Oncogene       Date:  2016-05-09       Impact factor: 9.867

4.  Expression and significance of Musashi-1 in gastric cancer and precancerous lesions.

Authors:  Rong-Guang Kuang; Yan Kuang; Qing-Feng Luo; Cheng-Jun Zhou; Rui Ji; Jian-Wen Wang
Journal:  World J Gastroenterol       Date:  2013-10-21       Impact factor: 5.742

5.  Knockdown of ZNF403 inhibits cell proliferation and induces G2/M arrest by modulating cell-cycle mediators.

Authors:  Rui Guan; Xiao-Yan Wen; Jing Wu; Rongqi Duan; Huibi Cao; Simon Lam; Defu Hou; Youdong Wang; Jim Hu; Zhuchu Chen
Journal:  Mol Cell Biochem       Date:  2012-02-19       Impact factor: 3.396

6.  High mobility group-box 3 overexpression is associated with poor prognosis of resected gastric adenocarcinoma.

Authors:  Hua-Rong Tang; Xian-Qin Luo; Gang Xu; Yan Wang; Zhi-Jun Feng; Hui Xu; Ya-Wei Shi; Qin Zhang; Li-Guang Wu; Chun-Quan Xue; Cheng-Wei Wang; Chao-Yang Wu
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

7.  Rhamnogalacturonan from Acmella oleracea (L.) R.K. Jansen: gastroprotective and ulcer healing properties in rats.

Authors:  Daniele Maria-Ferreira; Luisa Mota da Silva; Daniel Augusto Gasparin Bueno Mendes; Daniela de Almeida Cabrini; Adamara Machado Nascimento; Marcello Iacomini; Thales Ricardo Cipriani; Adair Roberto Soares Santos; Maria Fernanda de Paula Werner; Cristiane Hatsuko Baggio
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

8.  Clinicopathological and prognostic significance of Ki-67, caspase-3 and p53 expression in gastric carcinomas.

Authors:  Li-Jun Xiao; Shuang Zhao; En-Hong Zhao; Xin Zheng; Wen-Feng Gou; Yasuo Takano; Hua-Chuan Zheng
Journal:  Oncol Lett       Date:  2013-08-19       Impact factor: 2.967

9.  Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression in gastric cancer: a systematic review and meta-analysis.

Authors:  Gang Liu; Disheng Xiong; Junjie Zeng; Borong Chen; Zhengjie Huang
Journal:  Onco Targets Ther       Date:  2017-09-01       Impact factor: 4.147

10.  Ki67--An unsuitable marker of gastric cancer prognosis unmasks intratumoral heterogeneity.

Authors:  Christine Böger; Hans-Michael Behrens; Christoph Röcken
Journal:  J Surg Oncol       Date:  2015-12-28       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.